Louisiana State Employees Retirement System Takes $2.18 Million Position in Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Louisiana State Employees Retirement System acquired a new stake in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund acquired 17,700 shares of the specialty pharmaceutical company’s stock, valued at approximately $2,177,000.

Several other institutional investors have also recently bought and sold shares of the company. Captrust Financial Advisors lifted its stake in Jazz Pharmaceuticals by 2.4% in the 1st quarter. Captrust Financial Advisors now owns 3,707 shares of the specialty pharmaceutical company’s stock valued at $577,000 after acquiring an additional 86 shares in the last quarter. First Republic Investment Management Inc. lifted its stake in Jazz Pharmaceuticals by 0.7% in the 4th quarter. First Republic Investment Management Inc. now owns 12,062 shares of the specialty pharmaceutical company’s stock valued at $1,922,000 after acquiring an additional 88 shares in the last quarter. Daiwa Securities Group Inc. lifted its stake in Jazz Pharmaceuticals by 2.5% in the 3rd quarter. Daiwa Securities Group Inc. now owns 4,076 shares of the specialty pharmaceutical company’s stock valued at $528,000 after acquiring an additional 100 shares in the last quarter. Utah Retirement Systems increased its position in shares of Jazz Pharmaceuticals by 0.9% during the 4th quarter. Utah Retirement Systems now owns 10,836 shares of the specialty pharmaceutical company’s stock worth $1,726,000 after purchasing an additional 100 shares during the last quarter. Finally, Prime Capital Investment Advisors LLC increased its position in shares of Jazz Pharmaceuticals by 4.3% during the 4th quarter. Prime Capital Investment Advisors LLC now owns 2,646 shares of the specialty pharmaceutical company’s stock worth $325,000 after purchasing an additional 108 shares during the last quarter. Institutional investors own 89.14% of the company’s stock.

Insiders Place Their Bets

In other Jazz Pharmaceuticals news, CFO Philip L. Johnson acquired 12,000 shares of the business’s stock in a transaction on Friday, March 1st. The shares were acquired at an average price of $119.65 per share, with a total value of $1,435,800.00. Following the completion of the transaction, the chief financial officer now owns 27,932 shares in the company, valued at $3,342,063.80. The acquisition was disclosed in a legal filing with the SEC, which is available at the SEC website. In other news, CFO Philip L. Johnson bought 12,000 shares of the stock in a transaction on Friday, March 1st. The shares were purchased at an average cost of $119.65 per share, for a total transaction of $1,435,800.00. Following the completion of the purchase, the chief financial officer now directly owns 27,932 shares in the company, valued at approximately $3,342,063.80. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CAO Patricia Carr sold 1,936 shares of the business’s stock in a transaction on Wednesday, March 6th. The shares were sold at an average price of $119.64, for a total value of $231,623.04. Following the sale, the chief accounting officer now owns 8,364 shares in the company, valued at $1,000,668.96. The disclosure for this sale can be found here. Insiders own 4.40% of the company’s stock.

Jazz Pharmaceuticals Trading Down 1.7 %

NASDAQ JAZZ opened at $107.10 on Thursday. The business has a 50 day simple moving average of $120.35 and a 200 day simple moving average of $122.69. The stock has a market capitalization of $6.75 billion, a P/E ratio of 17.50, a P/E/G ratio of 1.53 and a beta of 0.59. The company has a debt-to-equity ratio of 1.37, a current ratio of 2.24 and a quick ratio of 1.85. Jazz Pharmaceuticals plc has a one year low of $106.61 and a one year high of $146.70.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last announced its quarterly earnings results on Wednesday, February 28th. The specialty pharmaceutical company reported $4.40 earnings per share (EPS) for the quarter, missing the consensus estimate of $4.44 by ($0.04). Jazz Pharmaceuticals had a return on equity of 31.27% and a net margin of 10.82%. The firm had revenue of $1.01 billion during the quarter, compared to the consensus estimate of $1.01 billion. Research analysts expect that Jazz Pharmaceuticals plc will post 16.24 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several research firms have weighed in on JAZZ. Needham & Company LLC reaffirmed a “buy” rating and set a $220.00 price target on shares of Jazz Pharmaceuticals in a research report on Wednesday, March 20th. JPMorgan Chase & Co. boosted their target price on Jazz Pharmaceuticals from $170.00 to $190.00 and gave the stock an “overweight” rating in a report on Friday, March 22nd. Piper Sandler boosted their target price on Jazz Pharmaceuticals from $171.00 to $188.00 and gave the stock an “overweight” rating in a report on Wednesday, March 20th. Cantor Fitzgerald reissued an “overweight” rating and set a $180.00 target price on shares of Jazz Pharmaceuticals in a report on Wednesday, April 10th. Finally, UBS Group decreased their price objective on Jazz Pharmaceuticals from $135.00 to $131.00 and set a “neutral” rating on the stock in a report on Friday, March 1st. Two investment analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $195.08.

Jazz Pharmaceuticals Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.